COMP <GO>
RMD vs BSX // EV/EBITDA & P/E VALUATION
ResMed Inc. (NYSE) VS. Boston Scientific Corporation (NYSE) • 15-METRIC TALLY: RMD 7
— BSX 7
▲ EV/EBITDA & P/E VALUATION LEADER: BSX
LAST: $229.94 (-9.05%) • MKT CAP: $35.56B
valuation
19.9x
LAST: $41.98 (-1.66%) • MKT CAP: $61.87B
valuation
15.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMD VS. BSX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RMD | BSX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.40% | 69.00% | -9.60 | BSX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.90% | 9.20% | +13.70 | RMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.9x | 15.8x | +4.10 | BSX | /valuation <GO> |
| Free Cash Flow Yield | 4.67% | 5.91% | -1.24 | BSX | /fcf-yield <GO> |
| Operating Margin | 32.70% | 18.00% | +14.70 | RMD | /operating-margins <GO> |
| Net Profit Margin | 27.20% | 14.00% | +13.20 | RMD | /net-margins <GO> |
| Revenue Growth (YoY) | 9.80% | 19.90% | -10.10 | BSX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.87% | 0.00% | +0.87 | RMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.49 | 2.77 | +9.72 | RMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | RMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.1 | 43.0 | +17.10 | RMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 0.99 | -0.06 | BSX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.6x | 18.5x | +5.10 | BSX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.56B | $61.87B | -$26.31B | BSX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RMD REV | BSX REV | RMD GROSS % | BSX GROSS % | RMD FCF | BSX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.15B | $20.07B | 59.4% | 69.0% | $1.66B | $3.66B |
| FY 2024 | $4.69B | $16.75B | 56.7% | 68.6% | $1.30B | $2.65B |
| FY 2023 | $4.22B | $14.24B | — | — | $503.3M | $1.86B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMD // BETA 0.93
BSX // BETA 0.99